SCHEMBL17822993

SCHEMBL17822993

NC(=O)c1cccc(-c2[nH]c(-c3ccccc3)nc2-c2n[nH]c(=O)n2C2CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 6/20 0.43
CSNK1D P48730 3/20 0.42
CSNK1E P49674 3/20 0.42
MAPK14 Q16539 3/20 0.42
MAP2K4 P45985 2/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
GLA P06280 3/20 0.39
GAA P10253 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
AAK1 Q2M2I8 1/20 0.38
TTK P33981 1/20 0.38
FYN P06241 1/20 0.38
CPT1A P50416 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19715278 0.99 CHEK2 (0.42) CHEK2CSNK1DCSNK1EMAPK14MAP2K4
SCHEMBL17823083 0.91 KDM4E (0.42) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
Hydrochloric Acid SCHEMBL17823071 0.90 KDM4E (0.41) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
SCHEMBL17823092 0.88 LRRK2 (0.42) CHEK2CSNK1DCSNK1EMAPK14KDM4E
SCHEMBL17823031 0.88 ALDH1A1 (0.39) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
Hydrochloric Acid SCHEMBL17822988 0.87 LRRK2 (0.41) CHEK2CSNK1DCSNK1EMAPK14KDM4E
Hydrochloric Acid SCHEMBL17823066 0.87 KMT2A (0.38) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
SCHEMBL19715268 0.83 MAPK14 (0.41) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
SCHEMBL17832405 0.83 KMT2A (0.40) CSNK1DCSNK1EMAPK14KDM4EALDH1A1
SCHEMBL21374212 0.82 KDM4E (0.42) MAPK14KDM4EALDH1A1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207474-B Substituted heterocycles as bromodomain inhibitors 恒翼生物医药科技(上海)有限公司 2021-05-07 CN claimed
EP-3230277-B1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD (CA) 2019-09-18 EP claimed
US-10292968-B2 Substituted heterocycles as bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2019-05-21 US claimed
US-20170360756-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US claimed
EP-3230277-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS Zenith Epigenetics Ltd. (CA) 2017-10-18 EP claimed
WO-2016092375-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2016-06-16 WO claimed
CN-107207474-B Substituted heterocycles as bromodomain inhibitors 恒翼生物医药科技(上海)有限公司 2021-05-07 CN disclosed
EP-3230277-B1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD (CA) 2019-09-18 EP disclosed
US-10292968-B2 Substituted heterocycles as bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2019-05-21 US disclosed
US-10292968-B2 Substituted heterocycles as bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2019-05-21 US disclosed
US-20170360756-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
US-20170360756-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
US-20170360756-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
EP-3230277-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS Zenith Epigenetics Ltd. (CA) 2017-10-18 EP disclosed
WO-2016092375-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360756-A1 SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 CHEK2 531/4885CSNK1D 200/4885CSNK1E 138/4885
US-10292968-B2 Substituted heterocycles as bromodomain inhibitors BRD4, BRD3, BRD1 CHEK2 531/4885CSNK1D 200/4885CSNK1E 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.